Get the Stockscreener App
149.52
2.18%
3.19
After Hours:
149.52
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Merck Co Inc stock is traded at $149.52, with a volume of 12.30M.
It is up +2.18% in the last 24 hours and up +2.90% over the past month.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
See More
Previous Close:
$146.33
Open:
$149.55
24h Volume:
12.30M
Relative Volume:
1.10
Market Cap:
$368.89B
Revenue:
$65.51B
Net Income/Loss:
$8.93B
P/E Ratio:
42.08
EPS:
3.5532
Net Cash Flow:
$14.12B
1W Performance:
+2.93%
1M Performance:
+2.90%
6M Performance:
+36.95%
1Y Performance:
+73.30%
1-Day Range:
$147.40
$151.35
1-Week Range:
$139.21
$151.35
52-Week Range:
$82.01
$156.92
Merck Co Inc Stock (MRK) Company Profile
Name
Merck Co Inc
Sector
Industry
Phone
908-740-4000
Address
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Compare MRK vs LLY, JNJ, ABBV, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
149.52 | 368.89B | 65.51B | 8.93B | 14.12B | 3.5532 |
LLY
Lilly Eli Co
|
1,417.54 | 1.26T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
273.20 | 657.68B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
294.89 | 521.11B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
160.79 | 303.67B | 54.66B | 13.58B | 16.05B | 7.0171 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-26 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-20-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-12-26 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-06-26 | Resumed | Citigroup | Neutral |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Feb-13-26 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-08-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-18-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-24-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Oct-13-25 | Resumed | Citigroup | Neutral |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Feb-18-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Feb-10-25 | Downgrade | TD Cowen | Buy → Hold |
| Jan-08-25 | Downgrade | Truist | Buy → Hold |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Dec-04-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-11-24 | Downgrade | Daiwa Securities | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Mar-11-24 | Downgrade | Societe Generale | Hold → Sell |
| Jan-04-24 | Upgrade | TD Cowen | Market Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Oct-27-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Oct-20-23 | Upgrade | UBS | Neutral → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Hold |
| Apr-13-23 | Upgrade | Citigroup | Neutral → Buy |
| Mar-28-23 | Downgrade | Societe Generale | Buy → Hold |
| Mar-13-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-06-23 | Initiated | Jefferies | Buy |
| Feb-22-23 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-04-23 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Oct-10-22 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-14-22 | Upgrade | Berenberg | Hold → Buy |
| Jul-06-22 | Upgrade | Daiwa Securities | Neutral → Buy |
| Jun-06-22 | Resumed | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-16-21 | Initiated | Daiwa Securities | Neutral |
| Dec-13-21 | Downgrade | UBS | Buy → Neutral |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Dec-07-21 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-29-21 | Downgrade | Citigroup | Buy → Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-01-21 | Upgrade | Argus | Hold → Buy |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-27-21 | Resumed | Truist | Buy |
| May-20-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Aug-03-20 | Upgrade | Goldman | Neutral → Buy |
| Jun-12-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-16-19 | Initiated | SVB Leerink | Outperform |
| Jul-03-19 | Initiated | Mizuho | Buy |
| May-28-19 | Initiated | Goldman | Neutral |
| May-13-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-16-18 | Reiterated | Citigroup | Buy |
| Oct-09-18 | Resumed | Guggenheim | Buy |
| Apr-23-18 | Upgrade | Goldman | Neutral → Buy |
| Apr-17-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-05-18 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-12-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Feb-14-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-07-18 | Reiterated | Morgan Stanley | Equal-Weight |
| Jan-16-18 | Upgrade | SunTrust | Hold → Buy |
View All
Merck Co Inc Stock (MRK) Latest News
AZN Q3 Earnings Beat Estimates, Oncology Drugs Drive Sales Growth - Zacks Investment Research
Company News for Oct 30, 2026 - Zacks Investment Research
Merck & Co., Inc. (MRK) Seasonal returns chart - Yahoo Finance Singapore
Dow Jones Top Movers for Oct. 29, 2026: Merck and Nike Lead Gainers, Alphabet and Caterpillar Fall - ChartMill
Why is Merck Stock Trading Higher Today?Merck & Co (NYSE:MRK) - Benzinga
Lilly And Merck Look To Compete In First-Line KRAS G12C Lung Cancer - Scrip
Merck to boost next decade revenue forecast on new drugs optimism - Reuters
GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth? - Zacks Investment Research
MRK Q3 Earnings & Sales Beat Estimates, '26 EPS View Raised, Stock Up - Zacks Investment Research
Merck & Co Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Merck & Co Inc Stock (MRK) Moved Up by 4.88% on Oct 29: A Full Analysis - TradingKey
Merck raises annual targets - marketscreener.com
Merck Boosts Profit Forecast as Key Medicines Top Estimates - Bloomberg.com
MERCK & CO. INC. (MRK.VI) Q3 FY2026 earnings call transcript - Yahoo Finance
Merck & Co., Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 - www.marketscreener.com
Merck & Co., Inc. Raises Earnings Guidance for the Year 2026 - marketscreener.com
Merck shares rise over 5% as drugmaker raises sales outlook - Proactive financial news
Merck stock rises as Q3 earnings beat estimates, 2026 outlook raised (MRK:NYSE) - Seeking Alpha
Merck (MRK) Surpasses Q3 Earnings and Revenue Estimates - Zacks Investment Research
Merck's Q3 sales up 5% to $18.1 billion - Breakingthenews.net
Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2026 Financial Results; Highlights Multiple Milestones Advancing Broad, Diverse Pipeline - Business Wire
Could Revolution Medicines Be a Millionaire-Maker Stock? - The Motley Fool
Will Moderna Soar on Nov. 6? - The Motley Fool
12,469 Merck & Co., Inc. $MRK Shares Sold by Bokf Na - MarketBeat
Pharma giants Merck, Eli Lilly face earnings health check (MRK:NYSE) - Seeking Alpha
Dear Merck Stock Fans, Mark Your Calendars for October 29 - Barchart.com
Jefferies & Co Adjusts Merck Price Target to $177 From $176 - www.marketscreener.com
Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026? - The Motley Fool
Gilead to Report Q3 Earnings: How Should You Play the Stock Now? - Zacks Investment Research
What's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings? - Zacks Investment Research
What's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings? - TradingView
Is Merck Stock a Buy, Sell or Hold Ahead of Q3 Earnings? - TradingView
Merck & Co., Inc. $MRK Position Lifted by Oppenheimer & Co. Inc. - MarketBeat
Leo Wealth LLC Makes New Investment in Merck & Co., Inc. $MRK - MarketBeat
23,115 Merck & Co., Inc. $MRK Shares Sold by apricus wealth LLC - MarketBeat
Merck & Co., Inc. (MRK) Shareholder/Analyst PresentationSlideshow (NYSE:MRK) 2026-10-26 - Seeking Alpha
Merck Highlights Phase III Cancer Wins, Eyes 2027 Oncology Pipeline Catalysts - MarketBeat
Merck Highlights Phase III Cancer Wins, Eyes 2027 Oncology Pipeline Catalysts - Yahoo Finance
A Look at Merck & Co Inc (MRK) After 3.2% Decline -- GF Value $1 - GuruFocus
Merck drug extends survival in endometrial cancer trial, wins US priority review - Reuters
Is Merck & Co (NYSE:MRK) Ready for Its Next Business Chapter? - Kalkine Media
Merck Drug Boosts Survival From Hard-to-Treat Uterine Cancer - Bloomberg.com
Should You Buy, Hold, or Sell BMY Stock Ahead of Q3 Earnings? - Zacks Investment Research
Merck Endometrial Cancer Studies Show Significant Survival Gains - Benzinga
Merck & Co Inc Stock (MRK) Moved Down by 3.21% on Oct 26: What Signal Does It Send? - TradingKey
Which Pharmaceutical ETF Is the Better Buy: iShares’ Domestic IHE or VanEck’s Global PPH? - The Motley Fool
Barclays Issues Positive Forecast for Merck & Co., Inc. (NYSE:MRK) Stock Price - MarketBeat
Breakfast News: Science Strikes Back at Cancer - The Motley Fool
Is First Trust Capital Strength ETF (FTCS) a Strong ETF Right Now? - Zacks Investment Research
Microbiotica Presents Phase 1b Clinical Data on MB097 at the European Society for Medical Oncology (ESMO) Congress 2026 - GlobeNewswire Inc.
Merck Co Inc Stock (MRK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Merck Co Inc Stock (MRK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| CHIRFI GUINDO | Officer |
Aug 13 '26 |
Proposed Sale |
135.00 |
10,000 |
1,350,000 |
0 |
| JENNIFER L ZACHARY | Officer |
Aug 12 '26 |
Proposed Sale |
133.46 |
80,315 |
10,718,495 |
0 |
| RICHARD ROBERT DELUCA JR | Officer |
Aug 12 '26 |
Proposed Sale |
131.63 |
11,699 |
1,539,992 |
0 |
| DeLuca Richard R. | EVP&Pres, Merck Animal Heallth |
Aug 12 '26 |
Sale |
131.63 |
11,699 |
1,539,992 |
110,167 |
| Zachary Jennifer | EVP, General Counsel |
Aug 12 '26 |
Option Exercise |
109.78 |
54,927 |
6,029,637 |
125,824 |
| Zachary Jennifer | EVP, General Counsel |
Aug 12 '26 |
Sale |
133.46 |
80,315 |
10,718,495 |
45,509 |
| DeLuca Richard R. | EVP&Pres, Merck Animal Heallth |
Aug 11 '26 |
Sale |
131.76 |
12,837 |
1,691,426 |
121,866 |
| RICHARD ROBERT DELUCA JR | Officer |
Aug 11 '26 |
Proposed Sale |
131.76 |
12,837 |
1,691,426 |
0 |
| DeLuca Richard R. | EVP&Pres, Merck Animal Heallth |
Aug 10 '26 |
Sale |
130.43 |
20,784 |
2,710,951 |
134,703 |
| RICHARD ROBERT DELUCA JR | Officer |
Aug 10 '26 |
Proposed Sale |
130.43 |
20,784 |
2,710,951 |
0 |
0.19%
7.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):